RxDoctor Payments DataLook up a doctor →

Claire Drummond, PA

Physician Assistant · Gonzales, LANPI 1881848877

Payments from drug & device makers

$10,021in general payments, 2019–2025

Across 653 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Bayer$891
  • GSK$880
  • Astellas Pharma US Inc$663
  • Novo Nordisk$648
  • Lilly USA, LLC$616
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$9,87599%
  • Education$1461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,021 in reported general payments places this provider in the 95th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Medicare billing

Part B allowed, 2024
$29,848
Medicare patients
81
Services billed
742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide250$301,251
JardianceEmpagliflozin104$115,920
OzempicSemaglutide83$113,166
Tresiba Flextouch U-200Insulin Degludec42$31,413
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$30,505
MyrbetriqMirabegron30$20,829
EliquisApixaban15$16,226
LinzessLinaclotide20$15,270
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$10,193
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$9,722
VascepaIcosapent Ethyl17$7,868
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$7,474
FarxigaDapagliflozin Propanediol13$7,415
VeozahFezolinetant11$6,045
Synjardy XrEmpagliflozin/Metformin Hcl11$4,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$616$301,251250 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr, Synjardy$465$134,667149 claims
Novo NordiskOzempic$648$113,16683 claims
GSKTrelegy Ellipta$880$30,50540 claims
Astellas Pharma US IncMyrbetriq, Veozah$663$26,87441 claims
PfizerEliquis$300$16,22615 claims
AbbVieLinzess$1,827$15,27020 claims
AstraZenecaFarxiga$60$7,41513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Gonzales

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →